婴儿痉挛新药-氨己烯酸片

Infantile spasms (IS) is an age-dependent epileptic encephalopathy with an incidence rate of approximately 3.1/10 000 live births1. Most of the symptoms begin in early infancy, and a few may persist into early childhood, or may occur for the first time in early childhood. Therefore, in 2010, the International League Against Epilepsy considered epileptic spasms to be a more appropriate description of the disease than IS. At present, the first-line drugs recognized at home and abroad for the treatment of IS are adrenocorticotropic hormone (ACTH) and . The current situation in our country is that there is a shortage of ACTH drug sources, and vigabatrin has not been approved for marketing in mainland China, but its effect is very good.

Vigabatrin is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor and was approved by the US FDA in 2009. After excluding IS caused by tuberous sclerosis (TSC), 107 children with IS were randomly treated with corticosteroids and vigabatrin. The 14-day effective rates were 76% and 52% respectively. In one study, 180 children with newly diagnosed IS were all initially treated with vigabatrin, and the average rate of complete control of spasticity within 5 days was 56.9%. It was also reported that 230 children with IS from 22 medical centers were initially treated with ACTH, oral hormones, and vigabatrin, and the effective rates were 55%, 39%, and 36% respectively. In the 2012 American guidelines and the 2016 German-speaking countries guidelines, vigabatrin is the first-line drug for the treatment of IS.

Fatigue, confusion, edema, alopecia, nystagmus, drowsiness, depression, memory loss, diplopia, weight gain, gastrointestinal disorders, headache, dizziness, nervousness, paresthesia, irritability, ataxia, tremor, etc. have been reported in clinical trials.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.